SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment.
SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment. J BUON. 2019 Sep-Oct;24(5):2099-2106 Authors: Rucinska M, Osowiecka K, Kieszkowska Grudny A, Nawrocki S Abstract PURPOSE: The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT. METHODS: A prospective single-institution clinical study was conducted among previously untreated patients with histologically confirmed localized prostate cancer. Patients were treated with SBRT: 33.5 Gy in 5 fractions. RESULTS: A total of 68 men with clinical stage of prostate cancer T1c-T2cN0M0 were included in the study. The median combined Gleason score was 6, the median PSA level was 10ng/mL. The median follow-up period was 48 months. Five years after the end of radiotherapy, the median PSA levels were as follows: 0.29ng/mL for all patients, 0.39ng/mL for those who did not receive androgen deprivation therapy, 0.25ng/mL for patients who underwent 6 months and 0.31ng/mL for patients who underwent 2-3 years of hormone therapy. Median nadir PSA levels were 0.025ng/mL for all patients and 0.48ng/mL for patients without hormone therapy. Low PSA nadir (
This study is a multicentre, randomised, open-label, phase 3 trial. Patients with localised prostate cancer whose PSA concentrations had decreased to
Conclusions: Hypofractionated radiotherapy appears to be equally tolerated compared to conventional fractionation in the early setting. Longer follow up is needed to assess the late toxicity profile of the patients and any potential differences between the control and experimental arm.
Conditions: Positive Lymph Node; Prostate Adenocarcinoma; PSA Level Greater Than Zero; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage I...
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Just one high dose of radiation to the heart can significantly reduce episodes...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Salvage radiation therapy (SRT) is recommended for men with biochemically recurrent prostate cancer post-radical prostatectomy. RTOG 9601 was a randomized phase 3 clinical trial that demonstrated an overall survival (OS) benefit from the addition of long-term anti-androgen therapy to SRT. However, hormone therapy has well documented side effects and has been shown to increase cardiac event rates, and there remains no evidence of an OS benefit from hormone therapy for men treated with early SRT. Herein, we aim to determine if pre-SRT PSA can serve as both a prognostic and predictive biomarker of benefit or harm from hormone therapy.
Conclusions: Fluoroscopy and 3D CT image-guided interstitial brachytherapy is feasible and appears to be a suitable treatment technique for patients with clinically localized prostate cancer after previous rectal resection and external beam radiation therapy. PMID: 31435432 [PubMed]
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
ConclusionsIn this phase 1/2 study, hypofractionated postoperative radiation therapy seems to have good clinical efficacy without significant late toxicity. Phase 3 studies are warranted.
ConclusionsLong-term QOL and late toxicity are favorable following postprostatectomy radiation therapy. Identifiable clinical and dosimetric risk factors may guide decision making to optimize urinary, sexual, and bowel function.Patient summaryThe following study provides a detailed report of favorable patient-reported quality of life and late side-effect profiles of radiation therapy following surgery for localized prostate cancer. Our findings provide patients guidance on what symptoms to expect if they are planning to undergo radiation therapy in this setting. It also allows physicians to counsel patients appropriately, ...